News

Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™ 08-07-2010
Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently... read more 

Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality - FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality 28-04-2010
Kiadis Pharma today provided an update on its cell therapy product ATIR™ developed for mismatched bone marrow transplants. ATIR™ continues to show excellent clinical results in patients who received a mismatched bone marrow transplantation from a family member donor. The two year follow up data... read more 

Partners

Dr. Denis-Claude Roy

Maisonneuve Rosemount Hospital, Montreal, Canada
Dr. Denis-Claude Roy from the University of Montreal, Canada is our leading academic partner for the development of our blood cancer products and has collaborated with Kiadis Pharma for many years. Dr. Roy significantly contributed to the developmen... read more 

Dr. Andrea Velardi

University of Perugia, Italy
Dr. Velardi from University of Perugia, Italy, is one of the foremost authorities on the development of haploidentical transplantation procedures. During the past two years, Dr. Velardi has evaluated the ability of ATIR™ and subsequently initiated... read more 

Dr. Stephan Mielke

Julius-Maximilians University of Würzburg, Germany
In Germany Kiadis Pharma collaborates with Dr. Stephan Mielke and Professor Dr. Hermann Einsele from the Allogeneic Stem Cell Transplant Center at the Julius-Maximilians University of Würzburg, Germany. Principal investigator of this collaboration w... read more 

Dr. John Barret and Dr. Stephan Mielke

The National Institutes of Health (NIH), USA
In the United States Kiadis Pharma collaborates with the NIH on its lead program ATIR™:The NIH team of Dr. Barrett, head of the transplantation unit, aims to significantly improve the outcome of hematopoietic stem cell transplantation (HSCT) procedur... read more 

Kiadis Pharma

Entrada 231-234
1096 EG  Amsterdam
The Netherlands


T +31 (0)20 314 02 50
F +31 (0)20 314 02 51